Progression of pulse pressure in kidney recipients durably exposed to CsA is a risk factor for epithelial phenotypic changes: An ancillary study of the CONCEPT trial

Transplant International

Volumn 27, Issue 4, 2014, Pages 344-352

  Xu Dubois, Yi Chun ^a,b   Hertig, Alexandre ^a,b   Lebranchu, Yvon ^c   Hurault De Ligny, Bruno ^d   Thervet, Eric ^e   Jauréguy, Maïté ^f   Touchard, Guy ^g   Le Pogamp, Patrick ^h   Le Meur, Yann ⁱ   Toupance, Olivier ^j   Heng, Anne Elisabeth ^k   Bayle, Francis ^l   Girardot Seguin, Sandrine ^m   Servais, Aude ^e   Meas Yedid, Vannary ⁿ   Rondeau, Eric ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CHU BRETONNEAU   (France)

^d CHG Clémenceau   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

^g POITIERS UNIVERSITY HOSPITAL   (France)

^h PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

ⁱ SERVICE DE RHUMATOLOGIE   (France)

^j HÔPITAL MAISON BLANCHE   (France)

^k Hopital Saint Jacques Clermont Ferrand   (France)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m Laboratoire Roche Pharma   (France)

ⁿ INSTITUT PASTEUR   (France)

more..

Author keywords

cyclosporin; epithelial to mesenchymal transition; interstitial fibrosis and tubular atrophy

Indexed keywords

CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPITHELIAL PHENOTYPIC CHANGE; FEMALE; FIBROGENESIS; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; ORGAN DONOR; PHENOTYPE; POST HOC ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; SINGLE BLIND PROCEDURE; STEROID THERAPY; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFECTS; EPITHELIUM; FIBROSIS; GRAFT REJECTION; KIDNEY; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

ADULT; BLOOD PRESSURE; CALCINEURIN INHIBITORS; CYCLOSPORINE; EPITHELIUM; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTORS; SIROLIMUS; TIME FACTORS;

EID: 84899444831     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12253     Document Type: Article

References (39)

1. Kihm LP, Hinkel UP, Michael K, et al,. Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus. Transplantation 2009; 88: 261.
2. Flechner SM, Kobashigawa J, Klintmalm G,. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
3. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J,. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777.
4. Stallone G, Di Paolo S, Schena A, et al,. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003; 75: 998.
5. Mota A, Arias M, Taskinen EI, et al,. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953.
6. Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, et al,. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115.
7. Lebranchu Y, Thierry A, Thervet E, Buchler M, Etienne I, Westeel PF, et al,. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011; 11: 1665.
8. Ruiz JC, Campistol JM, Grinyo JM, et al,. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004; 78: 1312.
9. Servais A, Meas-Yedid V, Toupance O, et al,. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009; 9: 2552.
10. Hamdy AF, El-Agroudy AE, Bakr MA, et al,. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 2005; 5: 2531.
11. Ponticelli C, Graziani G,. Proteinuria after kidney transplantation. Transpl Int 2012; 25: 909.
12. Rastaldi MP, Ferrario F, Giardino L, et al,. Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 2002; 62: 137.
13. Robertson H, Ali S, McDonnell BJ, Burt AD, Kirby JA,. Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol 2004; 15: 390.
14. Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF,. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 2005; 5: 1367.
15. Hertig A, Verine J, Mougenot B, et al,. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 2006; 6: 2937.
16. Hertig A, Anglicheau D, Verine J, et al,. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008; 19: 1584.
17. Galichon P, Hertig A,. Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside? Fibrogenesis Tissue Repair 2011; 4: 11.
18. Kers J, Xu-Dubois YC, Rondeau E, et al,. Intragraft tubular vimentin and CD44 expression correlate with long-term renal allograft function and interstitial fibrosis and tubular atrophy. Transplantation 2010; 90: 502.
19. Hazzan M, Hertig A, Buob D, et al,. Epithelial-to-mesenchymal transition predicts cyclosporine nephrotoxicity in renal transplant recipients. J Am Soc Nephrol 2011; 22: 1375.
20. Dean PG, Grande JP, Sethi S, et al,. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation 2008; 85: 1212.
21. Flechner SM, Kurian SM, Solez K, et al,. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776.
22. Xu-Dubois YC, Baugey E, Peltier J, et al,. Epithelial phenotypic changes are associated with a tubular active fibrogenic process in human renal grafts. Hum Pathol 2013; 44: 1251.
23. Galichon P, Vittoz N, Xu-Dubois YC, et al,. Epithelial phenotypic changes detect cyclosporine in vivo nephrotoxicity at a reversible stage. Transplantation 2011; 92: 993.
24. Servais A, Meas-Yedid V, Buchler M, et al,. Quantification of interstitial fibrosis by image analysis on routine renal biopsy in patients receiving cyclosporine. Transplantation 2007; 84: 1595.
25. Safar ME,. Peripheral pulse pressure, large arteries, and microvessels. Hypertension 2004; 44: 121.
26. Xu-Dubois YC, Galichon P, Brocheriou I, et al,. Expression of the transcriptional regulator snail 1 in kidney transplants displaying epithelial-to-mesenchymal transition features. Nephrol Dial Transplant 2013 [Epub ahead of print].
27. Vitalone MJ, O'Connell PJ, Jimenez-Vera E, et al,. Epithelial-to- mesenchymal transition in early transplant tubulointerstitial damage. J Am Soc Nephrol 2008; 19: 1571.
28. Lebranchu Y, Snanoudj R, Toupance O, et al,. Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study. Am J Transplant 2012; 12: 1801.
29. Snanoudj R, Royal V, Elie C, et al,. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11: 2635.
30. Thierry A, Thervet E, Vuiblet V, et al,. Long-term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. Am J Transplant 2011; 11: 2153.
31. Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V,. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008; 26: 2213.
32. Lehoux S,. Redox signalling in vascular responses to shear and stretch. Cardiovasc Res 2006; 71: 269.
33. Mitchell GF,. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol 2008; 105: 1652.
34. O'Rourke MF, Safar ME,. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46: 200.
35. Franklin SS,. Cardiovascular risks related to increased diastolic, systolic and pulse pressure. An epidemiologist's point of view. Pathol Biol (Paris) 1999; 47: 594.
36. Safar ME, Levy BI, Struijker-Boudier H,. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: 2864.
37. Safar ME, Delahousse M, Bahous SA,. Arterial stiffness and renal transplantation. J Hypertens 2008; 26: 2101.
38. Vetromile F, Szwarc I, Garrigue V, et al,. Early high pulse pressure is associated with graft dysfunction and predicts poor kidney allograft survival. Transplantation 2009; 88: 1088.
39. Barenbrock M, Hausberg M, Kosch M, Kisters K, Hoeks AP, Rahn KH,. A longitudinal study of vessel wall properties in normotensive and hypertensive renal transplant recipients. J Hum Hypertens 1998; 12: 707.